Perrigo cuts revenue, raises EPS guidance

The pharmaceutical company reported strong growth and record revenue and profit for the third fiscal quarter.

Perrigo Company (Nasdaq:PRGO; TASE:PRGO) reported record revenue and profits for its third fiscal quarter of 2012, which ended in March, but cut its revenue guidance for the fiscal year, which ends in June.

Revenue rose 13% to $778 million for the third fiscal quarter from $691.4 million from the corresponding quarter of 2011. $70 million of the growth came from the acquisitions of Paddock Laboratories Inc. and CanAm Care LLC, and $64 million was due to new product sales. These were partly offset by lower sales of certain current consumer healthcare and nutritional supplement products.

GAAP-based net profit rose to $115.7 million ($1.23 per share) for the third fiscal quarter from $92 million for the corresponding quarter, and non-GAAP net profit rose 32% to $132.7 million ($1.41per share) from $100.2 million. Perrigo beat the analysts' consensus of $1.21 per share but missed the revenue consensus of $825.1 million.

Perrigo raised its full-year non-GAAP earnings per share guidance to $4.90-$5.00 per share from $4.70-4.80, reflecting 22-25% growth over the corresponding quarter. However, it lowered its revenue growth forecast to 15-18% from 17-20%, citing a mild cold and flu season.

Consumer healthcare sales rose 6% to $449 million for the third fiscal quarter from $425 million for the corresponding quarter, due to $34 million in new product sales and $5 million in sales growth for existing products. Nutritionals segment sales fell to $118 million from $126 million, due to lower existing product sales of $27 million in the vitamins, minerals and supplements and infant formula segments, which were partly offset by $20 million in new product sales. Rx pharmaceuticals sales rose 84% to $156 million from $85 million, due to $62 million in sales from Paddock products.

Perrigo chairman and CEO Joseph Papa said that the new product launches would keep the company on track to exceed its $190 million new product sales goal for fiscal 2012. He added that the Rx segment continues to exceed expectations in both the existing and newly acquired businesses.

Perrigo's share price fell 5.6% in at the opening on Nasdaq to $98 giving a market cap of $9.6 billion, after falling 4.6% on the TASE to NIS 377.10.

Published by Globes [online], Israel business news - - on May 8, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס